title: Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects.
abstract: To evaluate the safety and efficacy of combining Endostar antiangiogenic therapy with neoadjuvant chemotherapy for the treatment of stage IIIA (N2) NSCLC, we conducted a randomized, controlled, open-label clinical study of 30 NSCLC patients. Patients were randomly assigned to the test or control groups, which received either two cycles of an NP neoadjuvant chemotherapy regimen combined with Endostar or the NP regimen alone, respectively, at a 2:1 ratio. Efficacy was assessed after 3 weeks, and surgical resection occurred within 4 weeks, in the 26 patients who successfully completed treatment. While total response rates (RR) and clinical benefit rates (CBR) did not differ between the experimental groups, total tumor regression rates (TRR) were higher in the test group than in the control group. Median DFS and OS also did not differ between the test and control groups. Clinical perioperative indicators, including intraoperative blood loss, number of dissected lymph node groups, duration of postoperative indwelling catheter use, and time to postoperative discharge, were comparable in the test and control groups. Finally, hematological and non-hematological toxicities and postoperative pathological indicators, including down-staging ratio, complete resection ratio, and metastatic lymph node ratio, also did not differ between the groups. Overall, combining Endostar with NP neoadjuvant chemotherapy increased therapeutic efficacy without increasing adverse effects in stage IIIA-N2 NSCLC patients. This study is registered with ClinicalTrials.gov (number NCT02497118).
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Xiaoliang
authors: X
authors: Zhao
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Yanjun
authors: Y
authors: Su
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Jian
authors: J
authors: You
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Liqun
authors: L
authors: Gong
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Zhenfa
authors: Z
authors: Zhang
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Meng
authors: M
authors: Wang
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Zhenqing
authors: Z
authors: Zhao
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Zhen
authors: Z
authors: Zhang
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Xiaolin
authors: X
authors: Li
authors: Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.|Tianjin Lung Cancer Center, Tianjin 300060, P.R. China.|Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.|National Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
authors: Changli
authors: C
authors: Wang
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007432:Intraoperative Period; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy*; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009362:Neoplasm Metastasis; D061214:Patient Safety; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors
keywords: neoadjuvant chemotherapy; non-small cell lung cancer; recombinant human endostatin